News & Perspective

Nov 27, 2001

Nov 27, 2001

CDC smallpox plan favors focused vaccination program over mass campaign

(CIDRAP News) – If smallpox reappears in the United States, health authorities will strive to trace and vaccinate everyone who has had contact with infected or exposed persons but probably will not mount any mass vaccination campaigns, according to a draft plan released Monday by the Centers for Disease Control and Prevention (CDC).

Dec 19, 2001

Dec 19, 2001

Anthrax vaccine to be offered to postal and Capitol workers

(CIDRAP News) – Because of a small theoretical risk that anthrax spores can hide in the lungs for up to 100 days and grow after antibiotic treatment is stopped, the anthrax vaccine and an extension of antibiotic treatment will be offered to people who may have been exposed in the recent anthrax attacks, federal health officials announced yesterday afternoon.

Dec 21, 2001

Dec 21, 2001

Congress approves $2.5 billion for bioterrorism preparedness

(CIDRAP News) – In a flurry of pre-adjournment activity yesterday, Congress appropriated about $2.5 billion for bioterrorism preparedness, including $1 billion for state and local efforts, according to an aide to Sen. Bill Frist, R-Tenn.

Jan 18, 2002

Jan 18, 2002

Military concerned over possible link between anthrax vaccine and birth defects

(CIDRAP News) – A preliminary study linking anthrax vaccinations in pregnant women with an increased risk of birth defects in their babies has prompted the US military to step up efforts to prevent immunization of pregnant women.

Feb 01, 2002

Feb 01, 2002

FDA clears BioPort to distribute anthrax vaccine

(CIDRAP News) – BioPort Corp of Lansing, Mich., yesterday received Food and Drug Administration (FDA) approval to begin routine distribution of its anthrax vaccine after more than 3 years of effort to bring its operation up to federal standards.

"FDA is now satisfied that BioPort's renovated facility can produce a vaccine that meets FDA standards for safety and efficacy," the agency said in a news release.

Feb 14, 2002

Feb 14, 2002

CDC says it's too soon to tell if anthrax vaccine increases risk of birth defects

(CIDRAP News) – The Centers for Disease Control and Prevention (CDC) says it will take several months to determine if women in the US military who received anthrax vaccine in the first trimester of pregnancy had a greater risk of bearing children with birth defects.

Mar 07, 2002

Mar 07, 2002

IOM says anthrax vaccine is safe and effective but needs improvement

(CIDRAP News) – A committee of the Institute of Medicine (IOM) has concluded after 17 months of study that the existing anthrax vaccine is effective and "acceptably safe," but a new vaccine that requires fewer doses and that causes fewer reactions is needed.

Mar 13, 2002

Mar 13, 2002

Fruits of computer hunt for anthrax antitoxin turned over to Defense Department

(CIDRAP News) – Data on more than 300,000 proteins that may have potential as treatments for anthrax—the fruits of a project in which thousands of personal computers were used to analyze billions of molecules—have been turned over to the US and United Kingdom governments.

Mar 25, 2002

Mar 25, 2002

In simulated smallpox attack, vaccine shortage crippled national response

(CIDRAP News) – It is 13 days since the emergence of a hypothetical smallpox epidemic caused by the release of virus in three US shopping malls. Some 16,000 cases have been reported, 1,000 people have died, and the nation is running out of vaccine. Hospitals are overflowing, and federal and state officials are at odds over how to contain the epidemic.

Mar 26, 2002

Mar 26, 2002

Cidofovir derivative shows promise as oral drug for smallpox

Laboratory and animal experiments suggest that a new, orally administered derivative of the antiviral drug cidofovir could be an effective treatment for smallpox.

Pages

Sort Results

 

Narrow results

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»